Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man
Identifieur interne : 002771 ( Main/Exploration ); précédent : 002770; suivant : 002772Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man
Auteurs : R. Raisman-Vozari ; J.-A. Girault [États-Unis] ; S. Moussaoui ; C. Feuerstein ; P. Jenner ; C. D. Marsden ; Yves Agid [France]Source :
- Brain Research [ 0006-8993 ] ; 1989.
English descriptors
- KwdEn :
Abstract
The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.
Url:
DOI: 10.1016/0006-8993(90)90520-L
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title>
<author><name sortKey="Raisman Vozari, R" sort="Raisman Vozari, R" uniqKey="Raisman Vozari R" first="R." last="Raisman-Vozari">R. Raisman-Vozari</name>
</author>
<author><name sortKey="Girault, J A" sort="Girault, J A" uniqKey="Girault J" first="J.-A." last="Girault">J.-A. Girault</name>
</author>
<author><name sortKey="Moussaoui, S" sort="Moussaoui, S" uniqKey="Moussaoui S" first="S." last="Moussaoui">S. Moussaoui</name>
</author>
<author><name sortKey="Feuerstein, C" sort="Feuerstein, C" uniqKey="Feuerstein C" first="C." last="Feuerstein">C. Feuerstein</name>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:FE34E2B9547A365626A3AD65A8E4BEAA74087A3B</idno>
<date when="1990" year="1990">1990</date>
<idno type="doi">10.1016/0006-8993(90)90520-L</idno>
<idno type="url">https://api.istex.fr/document/FE34E2B9547A365626A3AD65A8E4BEAA74087A3B/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">002F80</idno>
<idno type="wicri:Area/Main/Curation">002B90</idno>
<idno type="wicri:Area/Main/Exploration">002771</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man</title>
<author><name sortKey="Raisman Vozari, R" sort="Raisman Vozari, R" uniqKey="Raisman Vozari R" first="R." last="Raisman-Vozari">R. Raisman-Vozari</name>
<affiliation><wicri:noCountry code="subField">Paris France</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Girault, J A" sort="Girault, J A" uniqKey="Girault J" first="J.-A." last="Girault">J.-A. Girault</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Moussaoui, S" sort="Moussaoui, S" uniqKey="Moussaoui S" first="S." last="Moussaoui">S. Moussaoui</name>
<affiliation><wicri:noCountry code="subField">Grenoble France</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Feuerstein, C" sort="Feuerstein, C" uniqKey="Feuerstein C" first="C." last="Feuerstein">C. Feuerstein</name>
<affiliation><wicri:noCountry code="subField">Grenoble France</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
<affiliation><wicri:noCountry code="subField">London U.K.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation><wicri:noCountry code="subField">London U.K.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
<affiliation><wicri:noCountry code="subField">Paris France</wicri:noCountry>
<country>France</country>
<placeName><settlement type="city">Paris</settlement>
<region type="region" nuts="2">Île-de-France</region>
</placeName>
<orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Brain Research</title>
<title level="j" type="abbrev">BRES</title>
<idno type="ISSN">0006-8993</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1989">1989</date>
<biblScope unit="volume">507</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="45">45</biblScope>
<biblScope unit="page" to="50">50</biblScope>
</imprint>
<idno type="ISSN">0006-8993</idno>
</series>
<idno type="istex">FE34E2B9547A365626A3AD65A8E4BEAA74087A3B</idno>
<idno type="DOI">10.1016/0006-8993(90)90520-L</idno>
<idno type="PII">0006-8993(90)90520-L</idno>
<idno type="ArticleID">9090520L</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0006-8993</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>DARPP-32</term>
<term>Dopaminergic lesion</term>
<term>Parkinson</term>
<term>Phosphoprotein</term>
<term>Striatum</term>
<term>Tyrosine hydroxylase</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The present study was performed to determine the effect of a nearly complete nigrostriatal dopaminergic denervation on DARPP-32 levels in the striatum from animals and parkinsonian patients. DARPP-32 levels were estimated by in vitro phosphorylation in the presence of cAMP, or after inactivation of endogenous kinases and phosphatases, in the presence of the catalytic subunit of cAMP-dependent protein kinase. Intranigral 6-hydroxydopamine (6-OHDA) infusion in rats, or peripheral administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets, did not change striatal DARPP-32 levels. Postmortem studies, carried out on brains obtained shortly after death, from patients with Parkinson disease, or from patients with progressive supranuclear palsy, showed that the levels of striatal DARPP-32 were not different from controls. These results indicate that dopaminergic striatal denervation did not modify the amount of DARPP-32 in the striatum, suggesting that the expression of DARPP-32, a protein which mediates some of the effects of dopamine in striatal neurons, is independent from the dopaminergic innervation.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>États-Unis</li>
</country>
<region><li>État de New York</li>
<li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
<orgName><li>Hôpital de la Salpêtrière</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Feuerstein, C" sort="Feuerstein, C" uniqKey="Feuerstein C" first="C." last="Feuerstein">C. Feuerstein</name>
<name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
<name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<name sortKey="Moussaoui, S" sort="Moussaoui, S" uniqKey="Moussaoui S" first="S." last="Moussaoui">S. Moussaoui</name>
<name sortKey="Raisman Vozari, R" sort="Raisman Vozari, R" uniqKey="Raisman Vozari R" first="R." last="Raisman-Vozari">R. Raisman-Vozari</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Girault, J A" sort="Girault, J A" uniqKey="Girault J" first="J.-A." last="Girault">J.-A. Girault</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002771 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002771 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:FE34E2B9547A365626A3AD65A8E4BEAA74087A3B |texte= Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man }}
This area was generated with Dilib version V0.6.23. |